Preoperative/neoadjuvant therapy in pancreatic cancer

	Tweet

In research published this week in PLoS Medicine, Jörg Kleeff from Technische Universität München, and colleagues suggest that patients with apparently locally non-resectable tumors should be included in neoadjuvant protocols. The authors systematically reviewed studies concerning the effects of neoadjuvant therapy on tumor response, toxicity, resection, and survival percentages in pancreatic cancer.

Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related mortality and is associated with an extremely poor prognosis, with a median survival of 5-8 months. At present, the only chance for cure and prolonged survival is surgical resection. Currently approximately 10%-20% of patients are considered candidates for such resection.

The authors examined 111 studies, involving 4,394 patients, and found that a third of patients initially judged unresectable were able to undergo resection after neoadjuvant therapy. These patients were then found to have a similar survival rate to patients judged resectable before neoadjuvant treatment (the average survival time being 20.5 months after resection).

Although randomized trials are now needed to confirm this finding, they suggest that patients presenting with locally advanced/unresectable tumors should be offered neoadjuvant therapy and then re-evaluated for resection.

###

Funding
No direct funding was received for this study. The authors were personally salaried by their institutions during the period of writing (though no specific salary was set aside or given for the writing of this paper). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests
The authors have declared that no competing interests exist.

Citation
Gillen S, Schuster T, Meyer zum Buschenfelde C, Friess H, Kleeff J (2010) Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages. PLoS Med 7(4): e1000267. doi:10.1371/journal.pmed.1000267

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000267

Jörg Kleeff
Technische Universität München
Department of Surgery
Ismaningerstrasse 22
Munich, Bavaria 81675
Germany
49 89 4140 5098


Contact: Andrew Hyde

44-122-346-3330
Public Library of Science

RELATED STORIES:
Gene Linked to Pancreatic Cancer Growth   Surgery and Adjuvant Therapy Can Work for Pancreatic Cancer   Americans mixed on adequacy of cancer screenings: poll   Malaria drug slows pancreatic cancer growth in mouse models   A tumor of the pancreas mimicked by colonic duplication?   A promising approach in the prevention and treatment of pancreatic cancer   Avastin trial for pancreatic tumors   Johns Hopkins Scientists Crack Genetic Code for Form of Pancreatic Cancer   Some support for pancreatic cancer screening   November is Pancreatic Cancer Awareness Month   Pancreatic cancer risk varies with smoking habits   Metastasis of pancreatic cancer in action   Big belly raises a woman’s pancreatic cancer risk   Pancreatic cancer vaccine may improve survival   Red meat associated with pancreatic cancer   Tests may detect mesothelioma, pancreatic cancer   Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find   Mayo Clinic Reports New Findings on Noninvasive Test for Pancreatic Cancer   Methionine may ward off pancreatic cancer   New treatment combination safe for pancreatic cancer patients   Gene therapy tested in pancreatic cancer studies   New molecular therapy candidates for pancreatic cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]